Tue, Jul 29, 2014, 5:35 PM EDT - U.S. Markets closed


% | $
Click the to save as a favorite.

RXi Pharmaceuticals Corporation Message Board

  • mofisher22 mofisher22 Mar 14, 2013 10:53 PM Flag

    Red, or some other well versed long, aA question from a new long,

    since the deal with OPK last week. I must say I bought in fully because of the deal, I am very confident of Frost's investing ideas. Now, could you, or some other long, just in a nutshell, tell me how the deal impacts RXII, OPK, and Frost?

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • "Red" is a paid pumper. Why would anyone ask him anything?

      Sentiment: Strong Sell

    • I really have to do a bit more research on your question; however, see my thoughts below.

      RXI gained a pipeline overnight w/ the OPK deal. I am not sure of the specifics (that's where I need to do a bit more research). This makes RXI a much less risky investment for people. A one drug Biotech Company is like shooting a long range three at the buzzer. Only about 1 out of every 300 drugs make it through all 3 development phases. This is very scary for some investors (especially when the drug is in such early stages). There is a bit more security for investors now.

      I don't think that OPK had the expertise in RNA technology so they were looking to dump & focus on their strengths (what those are I do not know as I never heard of this company until this deal).

      As for Frost, I believe that he owns a #$%$ load of both of these companies.

      Anyone, please feel free to fill the gaps.

      Sentiment: Strong Buy

    • That is what I want to know, very good question. I think this volume is Frost buying shares just like he is buying shares of OPK. I am a buyer and holder now.

      Sentiment: Strong Buy

2.49-0.01(-0.40%)Jul 29 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.